{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:18Z","timestamp":1781650698272,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Wilson\u2019s Disease (WD) is a rare genetic disorder characterized by impaired hepatic copper elimination, potentially leading to chronic liver disease and cirrhosis. Although SARS-CoV-2 primarily affects the respiratory tract, hepatic involvement has been described. Using WD as a well-characterized model of a rare chronic liver disease with standardized long-term follow-up, we exploratively assessed short- and intermediate-term associations between SARS-CoV-2 infection and liver function as well as copper metabolism in patients with and without cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this longitudinal real-world study, we analyzed 71 WD patients (49 without cirrhosis, 22 with cirrhosis) with confirmed SARS-CoV-2 infection. Laboratory parameters, 24-hour urinary copper excretion (24-UCE), and transient elastography were assessed before infection (t0), shortly after infection (t1), and &gt;12 months post-infection (t2). Effect sizes (r) were calculated for intraindividual comparisons. Clinical severity, vaccination status, and long-COVID symptoms were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No patient required hospitalization. In WD patients without cirrhosis, liver enzymes, cholestasis markers, and copper metabolism remained stable across all timepoints, with predominantly very small effect sizes (|r| &lt; 0.3), indicating no clinically meaningful changes. In contrast, cirrhotic WD patients exhibited moderate to large short-term effects in transaminases and GGT (r up to 0.85) following infection. Bilirubin showed the most pronounced and persistent alteration in cirrhotic patients, with a sustained but only moderate effect (r \u2248 0.6) at long-term follow-up. Partial biochemical recovery was observed, yet normalization remained incomplete. Liver stiffness and copper parameters did not change significantly in either group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SARS-CoV-2 infection was associated with persistent biochemical alterations, particularly elevated bilirubin levels of moderate magnitude in WD patients with cirrhosis, while global liver function parameters remained largely stable. These findings highlight the need for close post-infection monitoring of WD patients with cirrhosis, even in mild SARS-CoV-2 infections, to mitigate potential hepatic complications and guide ongoing management in this vulnerable population. Nevertheless, these observations are hypothesis-generating and should be interpreted cautiously due to the small, selected cirrhotic subgroup, the lack of appropriate control groups, and the delayed timing of post-infection assessments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04840-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:09:06Z","timestamp":1776701346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory longitudinal cohort study of modest bilirubin-driven biochemical liver alterations after SARS-CoV-2 infection in a selected subgroup of patients with Wilson\u2019s disease and liver cirrhosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Sebastian","family":"K\u00f6hrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Lukas","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Langel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Langel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Michl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"4","key":"4840_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/hep.32805","volume":"77","author":"ML Schilsky","year":"2023","unstructured":"Schilsky ML, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428\u201355.","journal-title":"Hepatology"},{"key":"4840_CR2","unstructured":"European Association for the Study of the. L., EASL-ERN Clinical Practice Guidelines on Wilson\u2019s disease. J Hepatol, 2025."},{"issue":"1","key":"4840_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2005.087262","volume":"56","author":"U Merle","year":"2007","unstructured":"Merle U, et al. Clinical presentation, diagnosis and long-term outcome of Wilson\u2019s disease: a cohort study. Gut. 2007;56(1):115\u201320.","journal-title":"Gut"},{"issue":"2","key":"4840_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/mds.29292","volume":"38","author":"C Nilles","year":"2023","unstructured":"Nilles C, et al. Diagnosis and Outcomes of Late-Onset Wilson\u2019s Disease: A National Registry-Based Study. Mov Disord. 2023;38(2):321\u201332.","journal-title":"Mov Disord"},{"issue":"2","key":"4840_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-2007-971173","volume":"27","author":"RF Pfeiffer","year":"2007","unstructured":"Pfeiffer RF. Wilson\u2019s Disease. Semin Neurol. 2007;27(2):123\u201332.","journal-title":"Semin Neurol"},{"key":"4840_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/B978-0-444-63625-6.00011-2","volume":"142","author":"P Zimbrean","year":"2017","unstructured":"Zimbrean P, Seniow J. Cognitive and psychiatric symptoms in Wilson disease. Handb Clin Neurol. 2017;142:121\u201340.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"4840_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/infdis\/jiae484","volume":"231","author":"AA Butt","year":"2025","unstructured":"Butt AA, et al. COVID-19 Disease Incidence and Severity in Persons Previously Infected and Unvaccinated vs Previously Uninfected and Vaccinated. J Infect Dis. 2025;231(1):115\u201320.","journal-title":"J Infect Dis"},{"issue":"5","key":"4840_CR8","doi-asserted-by":"publisher","first-page":"e1003987","DOI":"10.1371\/journal.pmed.1003987","volume":"19","author":"D Buitrago-Garcia","year":"2022","unstructured":"Buitrago-Garcia D, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med. 2022;19(5):e1003987.","journal-title":"PLoS Med"},{"key":"4840_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071049","author":"W Shang","year":"2022","unstructured":"Shang W, et al. Percentage of asymptomatic infections among SARS-CoV-2 Omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10071049.","journal-title":"Vaccines"},{"issue":"38","key":"4840_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.15585\/mmwr.mm7338a1","volume":"73","author":"FP Havers","year":"2024","unstructured":"Havers FP, et al. COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged\u2009<\u20096 Months - COVID-NET, 12 States, October 2022-April 2024. MMWR Morb Mortal Wkly Rep. 2024;73(38):830\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"4840_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12072-020-10072-8","volume":"14","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14(5):690\u2013700.","journal-title":"Hepatol Int"},{"key":"4840_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040600","author":"TV Moga","year":"2023","unstructured":"Moga TV, et al. Impact of COVID-19 on patients with decompensated liver cirrhosis. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13040600.","journal-title":"Diagnostics"},{"issue":"4","key":"4840_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jhep.2022.07.008","volume":"77","author":"T Marjot","year":"2022","unstructured":"Marjot T, et al. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. 2022;77(4):1161\u201397.","journal-title":"J Hepatol"},{"key":"4840_CR14","doi-asserted-by":"publisher","first-page":"1039202","DOI":"10.3389\/fmed.2022.1039202","volume":"9","author":"O Keskin","year":"2022","unstructured":"Keskin O, et al. The impact of COVID-19 disease on the natural course of cirrhosis: Before and after starting vaccination. Front Med (Lausanne). 2022;9:1039202.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4840_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1186\/s12879-024-10223-4","volume":"24","author":"SY Chen","year":"2024","unstructured":"Chen SY, et al. Analyzing prognosis and comparing predictive scoring systems for mortality of COVID-19 patients with liver cirrhosis: a multicenter retrospective study. BMC Infect Dis. 2024;24(1):1315.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"4840_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s00535-021-01809-9","volume":"56","author":"Y Sumida","year":"2021","unstructured":"Sumida Y, Yoneda M. COVID-19-associated liver injury (COVALI): role of hepatologists. J Gastroenterol. 2021;56(8):786\u20137.","journal-title":"J Gastroenterol"},{"issue":"3","key":"4840_CR17","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.jhepr.2020.100113","volume":"2","author":"T Boettler","year":"2020","unstructured":"Boettler T, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113.","journal-title":"JHEP Rep"},{"issue":"1","key":"4840_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5501\/wjv.v12.i1.30","volume":"12","author":"D Walia","year":"2023","unstructured":"Walia D, Saraya A, Gunjan D. COVID-19 in patients with pre-existing chronic liver disease - predictors of outcomes. World J Virol. 2023;12(1):30\u201343.","journal-title":"World J Virol"},{"issue":"5","key":"4840_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","volume":"5","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"4840_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/jgh3.13031","volume":"7","author":"D Praharaj","year":"2023","unstructured":"Praharaj D, Premkumar M. Cirrhosis with COVID-19: just another infection or something more to it? JGH Open. 2023;7(12):809\u201311.","journal-title":"JGH Open"},{"issue":"18","key":"4840_CR21","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320.","journal-title":"N Engl J Med"},{"issue":"24","key":"4840_CR22","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMc2010419","volume":"382","author":"P Goyal","year":"2020","unstructured":"Goyal P, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"4840_CR23","first-page":"e70021","volume":"66","author":"I Mohr","year":"2025","unstructured":"Mohr I, et al. Mental and Physical Health in Wilson Disease Patients With SARS-CoV-2 Infection and Relevance of Long-COVID. JIMD Rep. 2025;66(3):e70021.","journal-title":"JIMD Rep"},{"issue":"2","key":"4840_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271\u2013e2808.","journal-title":"Cell"},{"issue":"2","key":"4840_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.31301","volume":"72","author":"F Lei","year":"2020","unstructured":"Lei F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020;72(2):389\u201398.","journal-title":"Hepatology"},{"issue":"3","key":"4840_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2020-322118","volume":"70","author":"JS Bajaj","year":"2021","unstructured":"Bajaj JS, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70(3):531\u20136.","journal-title":"Gut"},{"issue":"3","key":"4840_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","volume":"74","author":"T Marjot","year":"2021","unstructured":"Marjot T, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021;74(3):567\u201377.","journal-title":"J Hepatol"},{"issue":"10360","key":"4840_CR28","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","volume":"400","author":"U Agrawal","year":"2022","unstructured":"Agrawal U, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305\u201320.","journal-title":"Lancet"},{"issue":"2","key":"4840_CR29","doi-asserted-by":"publisher","first-page":"e0316529","DOI":"10.1371\/journal.pone.0316529","volume":"20","author":"S Dryden-Peterson","year":"2025","unstructured":"Dryden-Peterson S, et al. Severe outcomes of COVID-19 among adults with increased risk conditions: a population-based observational study. PLoS One. 2025;20(2):e0316529.","journal-title":"PLoS One"},{"key":"4840_CR30","doi-asserted-by":"publisher","first-page":"e070695","DOI":"10.1136\/bmj-2022-070695","volume":"378","author":"IL Ward","year":"2022","unstructured":"Ward IL, et al. Risk of COVID-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378:e070695.","journal-title":"BMJ"},{"issue":"4","key":"4840_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medj.2022.03.004","volume":"3","author":"K McMahan","year":"2022","unstructured":"McMahan K, et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med. 2022;3(4):262\u2013e2684.","journal-title":"Med"},{"issue":"10229","key":"4840_CR32","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"issue":"5","key":"4840_CR33","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/hep.31480","volume":"72","author":"A Bertolini","year":"2020","unstructured":"Bertolini A, et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology. 2020;72(5):1864\u201372.","journal-title":"Hepatology"},{"issue":"7","key":"4840_CR34","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.14309\/ajg.0000000000001264","volume":"116","author":"S Faruqui","year":"2021","unstructured":"Faruqui S, et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol. 2021;116(7):1414\u201325.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4840_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.32582","volume":"76","author":"L Hartl","year":"2022","unstructured":"Hartl L, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology. 2022;76(6):1563\u201375.","journal-title":"Hepatology"},{"issue":"3","key":"4840_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","volume":"73","author":"Q Cai","year":"2020","unstructured":"Cai Q, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566\u201374.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04840-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:25:58Z","timestamp":1781648758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04840-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4840"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04840-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective data collection was approved by the Ethics Committee of the University of Heidelberg (protocol number: S-565\/2011 and S-546\/2020), which complied with the provisions of the Good Clinical Practice guidelines and the Declaration of Helsinki and local laws and fulfilled Regulation (EU) 2016\/679 of the European Parliament and the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data (ID number DSAN854-A-OS\/5). Proof of informed consent is available upon request from the corresponding author [I Mohr].Written informed consent to participate in this study was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and\u00a0consent to participate"}},{"value":"Written informed consent for the procedure and management was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SK, MB, VL, HZ, AL and JL declare no COI. PM received Honoria for lectures from AstraZeneca, Falk and Abbvie. IM advises for Univar, Orphalan and MetaLead, received travel grants from Univar, is Principal Investigator on sponsored studies by Univar and received speaker\u2019s fees from Univar and Orphalan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}